E03O0020 Mouse Osteoprotegerin ELISA kit
The Mouse Osteoprotegerin ELISA kit can be used to identify samples from the mouse species. Osteoprotegerin can also be called CTNFRSF11B, TNFRSF11-B, OCIF, OPG, TR1, Tumor Necrosis Factor Receptor Superfamily Member 11b, Osteoclastogenesis Inhibitory Factor.
Product Information | |
Cat. No. | E03O0020 |
Product Name | Mouse Osteoprotegerin ELISA kit |
Species | Mouse |
Product Size | 48 Tests / 96 Tests |
Concentration | 50-1000pg/ml |
Sensitivity | 1.0pg/ml |
Principal | Competitive ELISA |
Sample Volume | 100 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 6.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 pg/ml | 1 vial |
STANDARD B (0.5mL) | 50 pg/ml | 1 vial |
STANDARD C (0.5mL) | 100 pg/ml | 1 vial |
STANDARD D (0.5mL) | 250 pg/ml | 1 vial |
STANDARD E (0.5mL) | 500 pg/ml | 1 vial |
STANDARD F (0.5mL) | 1000 pg/ml | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
OPG ELISA kit applies the competitive enzyme immunoassay technique utilizing an anti-OPG antibody and an OPG-HRP conjugate. The assay sample and buffer are incubated together with OPG-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the OPG concentration since OPG from samples and OPG-HRP conjugate compete for the anti-OPG antibody binding site. Since the number of sites is limited, as more sites are occupied by OPG from the sample, fewer sites are left to bind OPG-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The OPG concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between OPG and analogues was observed. | |
E03O0020 has been referenced in the below publications：
Influence of Eucommia Extracts on MC3T3-E1 Subclone 14 Osteoblast.
Studies of pharmacodynamic material basis of Eucommia ulmoides Oliv.
Studies on the anti-osteoporosis effective substances and quality control of Eucommia ulmoides based on MC3T3-E1 cell.
Low-Dose Staphylococcal Enterotoxin C2 Mutant Maintains Bone Homeostasis via Regulating Crosstalk between Bone Formation and Host T-Cell Effector Immunity.
Related Bluegene Biotech Products
BlueGene Biotech News
